Qatar Investment Authority

Ascend Elements Raises $542 Million to Accelerate Production of U.S.-engineered Lithium-Ion Battery Materials

Retrieved on: 
Wednesday, September 6, 2023
Hydro, Version One Ventures, EV, Mirae Asset Financial Group, CMA, Metal, QIA, CAM, Venture round, BIL, Carbon, DOE, Goldman Sachs, NMC, PULSE, JV, The Writing on the Wall, Tenaska, Temasek, Investment, Qatar Investment Authority, Element, United States Department of Energy, Security (finance), Cryptocurrency, Lithium, Renewable energy, Series

WESTBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Ascend Elements, a U.S.-based manufacturer of sustainable, engineered battery materials for electric vehicles, today announced it has raised $542 million in new equity investments, including $460 million in Series D investments and $82 million of additional investments from earlier this year. Ascend Elements' Series D round was led by Decarbonization Partners, Singapore-based investment firm Temasek, and Qatar Investment Authority (QIA). Other investors include Tenaska, Alliance Resource Partners, PULSE - CMA CGM Energy Fund, BHP Ventures, Fifth Wall, Hitachi Ventures, Mirae Asset, At One Ventures, Agave Partners, Alumni Ventures and other leading global investors.

Key Points: 
  • Ascend Elements' Series D round was led by Decarbonization Partners , Singapore-based investment firm Temasek , and Qatar Investment Authority (QIA).
  • The $542 million equity financing is one of the largest cleantech private placements in the United States of 2023.
  • Our sustainable lithium-ion battery materials will power EV batteries and accelerate the global transition to zero carbon emissions," said CEO Mike O'Kronley of Ascend Elements.
  • Several peer-reviewed studies have shown Ascend Elements' recycled battery materials perform as well as similar materials made from virgin (or mined) sources while reducing carbon emissions by up to 93%.

Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, OrbiMed, QIA, General partnership, Partner (business rank), Doctor of Philosophy, Star, Von Willebrand disease, Patient, Hematology, Biology, Growth, Therapy, Qatar Investment Authority, Pharmaceutical industry, MD

Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the closing of an oversubscribed $90 million Series C financing to continue growth of its first-in-class antibody therapies and portfolio companies.

Key Points: 
  • Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the closing of an oversubscribed $90 million Series C financing to continue growth of its first-in-class antibody therapies and portfolio companies.
  • Including this Series C round, Star Therapeutics has raised over $190 million since inception to create numerous portfolio companies.
  • This novel therapy is being developed by Vega Therapeutics, a Star portfolio company focused on underserved blood disorders.
  • We look forward to supporting Star as it continues to be an innovation engine for transformative therapies."

Adani Group's Stocks, Financials unaffected

Retrieved on: 
Saturday, September 2, 2023
TotalEnergies, QIA, Adani Group, Adani Green Energy, INR, Adani Ports & SEZ, Adani Power, EBITDA, Trust, Investment, Yoy, Qatar Investment Authority, Security (finance), IHC

The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.

Key Points: 
  • The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.
  • Four of the group's largest companies—Adani Enterprises, Adani Ports, Adani Green, and Adani Power—have gained over 100% from their lows.
  • Adani Ports, the most widely held institutional stock in the Adani portfolio, is now trading above its pre-report price.
  • Importantly, the Adani Group operates within the bounds of the law and under the scrutiny of regulatory authorities in respective jurisdictions.

Adani Group's Stocks, Financials unaffected

Retrieved on: 
Saturday, September 2, 2023
TotalEnergies, QIA, Adani Group, Adani Green Energy, INR, Adani Ports & SEZ, Adani Power, EBITDA, Trust, Investment, Yoy, Qatar Investment Authority, Security (finance), IHC

The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.

Key Points: 
  • The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.
  • Four of the group's largest companies—Adani Enterprises, Adani Ports, Adani Green, and Adani Power—have gained over 100% from their lows.
  • Adani Ports, the most widely held institutional stock in the Adani portfolio, is now trading above its pre-report price.
  • Importantly, the Adani Group operates within the bounds of the law and under the scrutiny of regulatory authorities in respective jurisdictions.

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

Retrieved on: 
Thursday, August 31, 2023
Exercise, BofA Securities, Code, NASH, SEC Rule 144A, Equity carve-out, Public company, Transaction, Loi autorisant le divorce en France, Commercial code, SGLT2, Person, Qatar Investment Authority, Sale, Royalty payment, NPV, Patient, European, Fatty liver disease, ISIN, United Kingdom, European Investment Bank, Phase, EIB, III, Pharmaceutical industry, Security (finance), Life insurance, Cryptocurrency, Bank, Real estate, Music, EU, Euronext Paris

As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.

Key Points: 
  • As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.
  • After the Capital Increase, Sofinnova Partner will hold 9.8% of the share capital of the Company, on a non-diluted basis.
  • After the Capital Increase, Yiheng Capital will hold 7.4% of the share capital of the Company, on a non-diluted basis.
  • The Royalty Certificates will not be listed on any stock exchange and will not be assigned an ISIN.

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

Retrieved on: 
Monday, August 14, 2023
Workforce, Partnership, ALF, SG, Schizophrenia, New Drug Application, Clinical trial, Part, Element, R, Sale, II, Breakthrough therapy, Selective serotonin reuptake inhibitor, Incidence, Nursing, Dementia, PEC, Hospital, Shanda, Patient, Administration, Protocol amending the Single Convention on Narcotic Drugs, Lunatic, Breakthrough, Toxicology, Webcast, Artificial intelligence, MAD, Research and development, Bipolar, AI, Research, FDA, Therapy, POC, Qatar Investment Authority, Agitation, Pharmacology, Safety, DSM-IV codes, Medical device, Fine chemical, Pharmaceutical industry, Medical imaging, Audit

ET today

Key Points: 
  • ET today
    NEW HAVEN, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second quarter ended June 30, 2023, and a strategic reprioritization to strengthen its focus and significantly reduce operating expenses.
  • Continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing or strategic partnership, M&A, or sale.
  • Net Loss: BioXcel Therapeutics had a net loss of $53.5 million for the second quarter of 2023, compared to a net loss of $37.7 million for the same period in 2022.
  • ET to discuss its second quarter 2023 financial results and provide an update on recent operational highlights.

Turnbridge Equities and Manekin Raise $275 million for Development of National Capital Business Park, including $110 million of Joint Venture Equity from Qatar Investment Authority and PCCP, and $165 million of Construction Financing from Apollo

Retrieved on: 
Tuesday, June 13, 2023
Professional Services, Commercial Building & Real Estate, Asset Management, Construction & Property, Urban Planning, PCCP, Partnership, I-95, QIA, Developer, Electricity, I-83, Apollo Global Management, HVAC, Qatar Investment Authority, Stock, NCBP, I-81, Capital Beltway, Ferguson Enterprises, Self storage, Turnbridge

The transaction included approximately $275 million of construction financing and joint venture equity for the recapitalization and development of Phase I of NCBP, consisting of five Class A industrial warehouse buildings totaling 1.3 million square feet.

Key Points: 
  • The transaction included approximately $275 million of construction financing and joint venture equity for the recapitalization and development of Phase I of NCBP, consisting of five Class A industrial warehouse buildings totaling 1.3 million square feet.
  • Phase I of National Capital Business Park consists of five Class A industrial warehouse buildings that will range in size from approximately 160,000 square feet to 360,000 square feet across 94 acres.
  • “The impressive, institutional capital stack we have assembled for this best-in-class development speaks to the quality of the Turnbridge and Manekin teams and the project they have assembled here.
  • This project is the perfect case study of the market today – competitive, sophisticated capital stepping up for infill projects and top sponsors.”

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

Retrieved on: 
Monday, June 5, 2023
GMP, ITM, Radionuclide, QIA, TRT, Supervisory board, Radiopharmaceutical, Glioblastoma, Carbyne, Temasek, Patient, III, Qatar Investment Authority, Pharmaceutical industry

The round comprised mostly of primary capital alongside a minority transaction of secondary shares.

Key Points: 
  • The round comprised mostly of primary capital alongside a minority transaction of secondary shares.
  • In addition, the company will expand its market-leading manufacturing capacities and infrastructure for n.c.a.
  • 177Lu, scale GMP-manufacturing for 225Ac, and expand in-house drug product manufacturing capabilities to accelerate the global access to radiopharmaceuticals worldwide.
  • “ITM is a leading radiopharmaceutical company with an advanced proprietary pipeline and has established itself as the major radioisotope supplier globally.

Builder.ai announces $250M Series D led by QIA to push new boundaries for its AI powered composable software platform

Retrieved on: 
Tuesday, May 23, 2023
DNA, JPMorgan Chase, Partnership, ICONIQ Capital, QIA, Venture round, Microsoft, LCAP, History, HQ, Investment, Magic, CIO, Entrepreneurship, AI, GTM, Insight, Duggal, Qatar Investment Authority, Insight Partners, Etisalat by e&, Software, Cryptocurrency, Medical device

The new investment, led by Qatar Investment Authority (QIA) takes the total amount raised by the company to over $450 million with an up to 1.8x increase in its valuation.

Key Points: 
  • The new investment, led by Qatar Investment Authority (QIA) takes the total amount raised by the company to over $450 million with an up to 1.8x increase in its valuation.
  • The Series D round included participation from additional existing and new investors including Iconiq Capital, Jungle Ventures & Insight Partners.
  • Today this means being able to build software to be able to do more with less.
  • It is what attracted our first-round investors in 2018, and what drives this Series D today.

Portfolio company Ensoma announces closing of Series B Extension

Retrieved on: 
Tuesday, May 16, 2023
LSE, Mirae Asset Financial Group, Investment, QIA, Biotechnology, Symbiosis, Bill & Melinda Gates Foundation, Viking Global Investors, Series, Bill, Fred Hutchinson Cancer Research Center, Qatar Investment Authority, Security (finance), Financial services

LONDON, 16 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its portfolio company Ensoma has closed an extension of its Series B financing, raising a further $50 million to bring the total round to $135 million.

Key Points: 
  • LONDON, 16 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its portfolio company Ensoma has closed an extension of its Series B financing, raising a further $50 million to bring the total round to $135 million.
  • The $50 million extension round was raised by new investors Kite, a Gilead Company, Bioluminescence Ventures, Delos Capital, and by existing investor SymBiosis.
  • Following the Series B extension, Arix’s percentage holding has been diluted from 7.6% to 6.1%.
  • The funds raised will enable the company to advance the development of its in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other applications.